Mineralys Therapeutics (MLYS) Other financing activities (2024 - 2026)

Mineralys Therapeutics has disclosed Other financing activities across 3 years of filings, most recently posting $1000.0 for Q1 2026.

• Other financing activities for Q1 2026 came in at $1000.0, down 90.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $382000.0 (changed 0.0% YoY), and the FY2025 annual result was $391000.0, down 10.11% from the prior year.
• Other financing activities came in at $1000.0 for Q1 2026 at Mineralys Therapeutics, down from $305000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $305000.0 in Q4 2025 to a low of $1000.0 in Q1 2026.
• The 3-year median for Other financing activities is $47000.0 (2024), against an average of $91888.9.
• Across the five-year window, Other financing activities soared 548.94% in 2025 and tumbled 90.0% in 2026, its largest moves.
• Mineralys Therapeutics' Other financing activities stood at $47000.0 in 2024, then jumped by 548.94% to $305000.0 in 2025, then tumbled by 99.67% to $1000.0 in 2026.
• The last three Other financing activities figures came in at $1000.0 (Q1 2026), $305000.0 (Q4 2025), and $29000.0 (Q3 2025), per Business Quant data.